全文获取类型
收费全文 | 1640342篇 |
免费 | 139284篇 |
国内免费 | 6652篇 |
专业分类
耳鼻咽喉 | 22057篇 |
儿科学 | 53287篇 |
妇产科学 | 46725篇 |
基础医学 | 231201篇 |
口腔科学 | 48028篇 |
临床医学 | 146066篇 |
内科学 | 318298篇 |
皮肤病学 | 34558篇 |
神经病学 | 131437篇 |
特种医学 | 66527篇 |
外国民族医学 | 494篇 |
外科学 | 248093篇 |
综合类 | 50970篇 |
现状与发展 | 13篇 |
一般理论 | 546篇 |
预防医学 | 126266篇 |
眼科学 | 37559篇 |
药学 | 126548篇 |
39篇 | |
中国医学 | 6913篇 |
肿瘤学 | 90653篇 |
出版年
2018年 | 16515篇 |
2016年 | 14547篇 |
2015年 | 17502篇 |
2014年 | 23522篇 |
2013年 | 34132篇 |
2012年 | 46045篇 |
2011年 | 48572篇 |
2010年 | 29015篇 |
2009年 | 27379篇 |
2008年 | 45359篇 |
2007年 | 47979篇 |
2006年 | 48628篇 |
2005年 | 46918篇 |
2004年 | 46588篇 |
2003年 | 45174篇 |
2002年 | 43960篇 |
2001年 | 77752篇 |
2000年 | 79537篇 |
1999年 | 66929篇 |
1998年 | 17325篇 |
1997年 | 15910篇 |
1996年 | 15661篇 |
1995年 | 16294篇 |
1994年 | 15286篇 |
1993年 | 14318篇 |
1992年 | 55553篇 |
1991年 | 53930篇 |
1990年 | 52689篇 |
1989年 | 50931篇 |
1988年 | 47277篇 |
1987年 | 46619篇 |
1986年 | 44321篇 |
1985年 | 42885篇 |
1984年 | 32005篇 |
1983年 | 27537篇 |
1982年 | 16093篇 |
1981年 | 14389篇 |
1980年 | 13499篇 |
1979年 | 30418篇 |
1978年 | 21020篇 |
1977年 | 17693篇 |
1976年 | 16648篇 |
1975年 | 17516篇 |
1974年 | 21450篇 |
1973年 | 20643篇 |
1972年 | 18841篇 |
1971年 | 17752篇 |
1970年 | 16270篇 |
1969年 | 15250篇 |
1968年 | 13935篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
45.
46.
Yue Wentao Zhang Enjie Liu Ruixia Zhang Yue Wang Chengrong Gao Shen Su Shaofei Gao Xiao Wu Qingqing Yang Xiaokui Papageorghiou Aris T. Yin Chenghong 《European journal of epidemiology》2022,37(3):295-304
European Journal of Epidemiology - The China birth cohort study (CBCS) is a prospective longitudinal, mega-cohort study and the first national-based birth cohort study, aiming to establish a birth... 相似文献
47.
48.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
49.
50.
Lauren E. Barber Kimberly A. Bertrand Shanshan Sheehy Laura F. White Hemant K. Roy Lynn Rosenberg Julie R. Palmer Jessica L. Petrick 《International journal of cancer. Journal international du cancer》2023,153(12):1978-1987
Evidence suggests that aspirin use reduces the occurrence of colorectal neoplasia. Few studies have investigated the association among Black Americans, who are disproportionately burdened by the disease. We assessed aspirin use in relation to colorectal adenoma among Black women. The Black Women's Health Study is a prospective cohort of self-identified Black American women established in 1995. Participants reported regular aspirin use on baseline and follow-up questionnaires. Beginning in 1999, participants reported undergoing a colonoscopy or sigmoidoscopy, the only procedures through which colorectal adenomas can be diagnosed. Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for associations between aspirin use and colorectal adenoma among 34 397 women who reported at least 1 colonoscopy or sigmoidoscopy. From 1997 through 2018, 1913 women were diagnosed with an adenoma. Compared to nonaspirin users, regular users had 14% (OR = 0.86, 95% CI: 0.78-0.95) lower odds of adenoma. The odds of adenoma decreased with increasing duration of aspirin use (≥10 years: OR = 0.80, 95% CI: 0.66-0.96). Initiating aspirin at a younger age was associated with a reduced adenoma occurrence (age < 40 years at initiation: OR = 0.69, 95% CI: 0.55-0.86). Regular aspirin use was associated with a decreased odds of colorectal adenoma in our study of Black women. These findings support evidence demonstrating a chemopreventive impact of aspirin on colorectal neoplasia and suggest that aspirin may be a useful prevention strategy among US Black women. 相似文献